Research Topics
Genomes and Genes | Peter S LinsleySummaryAffiliation: Merck Research Laboratories Country: USA Publications
| Collaborators
|
Detail Information
Publications
Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progressionPeter S Linsley
Rosetta Inpharmatics, LLC, 401 Terry Ave N, Seattle, WA 98109, USA
Mol Cell Biol 27:2240-52. 2007..Simultaneous silencing of these genes was more effective at blocking cell cycle progression than disruption of the individual genes. Thus, miR-16 coordinately regulates targets that may act in concert to control cell cycle progression...
Mustering the micromanagersLee P Lim
Nat Biotechnol 25:996-7. 2007
Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215Sara A Georges
Rosetta Inpharmatics LLC, Seattle, Washington WA 98109, USA
Cancer Res 68:10105-12. 2008..Our results showing a role for miR-192/215 in cell proliferation combined with recent observations that these miRNAs are underexpressed in primary cancers support the idea that miR-192 and miR-215 function as tumor suppressors...
Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analysesB Nelson Chau
Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck and Co, Inc, Seattle, Washington 98109, USA
Cancer Res 69:1368-74. 2009..Thus, our integrated genomic approach has led to the identification of a novel mediator of p53 network biology...
Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γPaul Warrener
Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck and Co, Inc, Seattle, WA 98109, USA
Apoptosis 17:691-701. 2012..These findings establish a link between synthetic lethality of PARPi in BRCA-network disrupted cells and interferon pathway activation triggered by genetic instability...
MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNTZhan Zhang
Rosetta Inpharmatics LLC, Seattle, WA, USA
Cell Cycle 8:2756-68. 2009..Thus, miR-210 influences the hypoxia response in tumor cells through targeting a key transcriptional repressor of the MYC-MAX network...
MicroRNA-like off-target transcript regulation by siRNAs is species specificJulja Burchard
Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
RNA 15:308-15. 2009..Therefore, siRNA therapeutics may trigger microRNA-like silencing of many unintended targets in vivo, and the potential toxicities caused by these off-target gene regulations cannot be accurately assessed in rodent models...
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencingAimee L Jackson
Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
RNA 12:1197-205. 2006....
PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophyXudong Dai
Informatics, Rosetta Inpharmatics, Seattle, Washington, United States of America
PLoS Comput Biol 3:e30. 2007..When combined with phenotypic evaluation, our approach should help to unleash the full potential of siRNAs in systematically unveiling the molecular mechanism of biological events...
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progressionIrena Ivanovska
Rosetta Inpharmatics LLC, 401 Terry Ave N, Seattle, WA 98109, USA
Mol Cell Biol 28:2167-74. 2008..We also show that miR-106b overrides a doxorubicin-induced DNA damage checkpoint. Thus, miR-106b family members contribute to tumor cell proliferation in part by regulating cell cycle progression and by modulating checkpoint functions...
T lymphocyte activation gene identification by coregulated expression on DNA microarraysMao Mao
Rosetta Inpharmatics LLC, Merck Research Laboratories, 401 Terry Avenue N, Seattle, WA 98109, USA
Genomics 83:989-99. 2004..Four of these ESTs were extended to novel full-length clones encoding T-cell-regulated proteins with predicted functions in GTP metabolism, cell organization, and signal transduction...
Functional genomics identifies therapeutic targets for MYC-driven cancerMasafumi Toyoshima
Department of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Proc Natl Acad Sci U S A 109:9545-50. 2012..In summary, through a functional genomics approach, pathways essential in the context of oncogenic MYC but not to normal cells were identified, thus revealing a rich therapeutic space linked to a previously "undruggable" oncogene...
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAsLee P Lim
Rosetta Inpharmatics, Merck and Co, 401 Terry Avenue N, Seattle, Washington 98109, USA
Nature 433:769-73. 2005..Moreover, miR-1 and miR-124, and presumably other tissue-specific miRNAs, seem to downregulate a far greater number of targets than previously appreciated, thereby helping to define tissue-specific gene expression in humans...
An optimized lentivirus-mediated RNAi screen reveals kinase modulators of kinesin-5 inhibitor sensitivityRichard A Klinghoffer
Rosetta Inpharmatics LLC, Merck and Co, Inc, Seattle, WA 98109, USA
Assay Drug Dev Technol 6:105-19. 2008..These results demonstrate the feasibility of screening with large collections of lentiviral vectors to identify drug enhancers and suppressors...
Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptionsSteven R Bartz
Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
Mol Cell Biol 26:9377-86. 2006..Thus, tumor cells having disruptions in BRCA1/2 network genes and TP53 together are more sensitive to cisplatin than cells with either disruption alone...
Myc-regulated microRNAs attenuate embryonic stem cell differentiationChin Hsing Lin
Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 4417, USA
EMBO J 28:3157-70. 2009..In contrast, knockdown of the endogenous miRNAs accelerate differentiation. Our data show that in ES cells c-Myc acts, in part, through a subset of miRNAs to attenuate differentiation...
Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarityAimee L Jackson
Rosetta Inpharmatics, LLC, Seattle, WA 98109, USA
RNA 12:1179-87. 2006..Thus, short stretches of sequence complementarity to the siRNA or shRNA seed region are key to the silencing of unintended transcripts...
Individual-specific variation of gene expression in peripheral blood leukocytesJerald P Radich
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4 100, Seattle, WA 98109, USA
Genomics 83:980-8. 2004..These studies demonstrate the feasibility of using DNA microarrays to measure the variations in gene expression of PBL from different individuals in response to environmental and genetic factors...
Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown miceAngus T De Souza
Rosetta Inpharmatics, Merck and Co Inc, 401 Terry Avenue North, Seattle, WA 98109, USA
Nucleic Acids Res 34:4486-94. 2006..Together, these data validate the utility of the RNAi approach and suggest that siRNA can be used as a complement to classical knockout technology in gene function studies...
MicroRNAs and cell cycle regulationMichael Carleton
Rosetta Inpharmatics LLC, Seattle, Washington 98109, USA
Cell Cycle 6:2127-32. 2007..We discuss emerging evidence that support the idea that some microRNA activity may be cell cycle dependent, and we outline how the coordinate regulation of microRNA targets may influence cell cycle progression...
Recent developments in DNA microarraysDaniel D Shoemaker
Rosetta Inpharmatics, 12040 115th Avenue North East, Kirkland, Washington 98034, USA
Curr Opin Microbiol 5:334-7. 2002..Supporting this view, the number of applications of DNA microarray technology has since expanded exponentially. Here, we review recent advances in microarray technology and selected new applications of the technology...
Expression profiling reveals off-target gene regulation by RNAiAimee L Jackson
Rosetta Inpharmatics LLC, 12040 115th Avenue NE, Kirkland, Washington 98034, USA
Nat Biotechnol 21:635-7. 2003..These results demonstrate that siRNAs may cross-react with targets of limited sequence similarity...
RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failureMichael Carleton
Rosetta Inpharmatics LLC, 401 Terry Ave, N Seattle, Washington 98109, USA
Mol Cell Biol 26:3853-63. 2006..Furthermore, the link we observed between siRNA efficacy and phenotypic outcome indicates that distinct stages during cell cycle progression are disrupted by the differential modulation of KIF14 expression...
Gene expression changes associated with progression and response in chronic myeloid leukemiaJerald P Radich
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Proc Natl Acad Sci U S A 103:2794-9. 2006..These studies point to specific gene pathways that might be exploited for both prognostic indicators as well as new targets for therapy...
Signatures of environmental exposures using peripheral leukocyte gene expression: tobacco smokeJohanna W Lampe
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Cancer Epidemiol Biomarkers Prev 13:445-53. 2004..These findings suggest that expression patterns can be used to identify a complex environmental exposure in humans...
Genetics of gene expression surveyed in maize, mouse and manEric E Schadt
Rosetta Inpharmatics, LLC, 12040 115th Avenue N E, Kirkland, Washington 98034, USA
Nature 422:297-302. 2003..We identify a gene expression pattern strongly associated with obesity in a murine cross, and observe two distinct obesity subtypes. Furthermore, we find that these obesity subtypes are under the control of different loci...
Noise amidst the silence: off-target effects of siRNAs?Aimee L Jackson
Rosetta Inpharmatics LLC, 401 Terry Avenue N, Seattle, WA 98109, USA
Trends Genet 20:521-4. 2004..In the meantime, caution is warranted in interpreting gene function and phenotypes resulting from RNAi experiments...
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulatorsGalina Gabriely
Center of Neurologic Diseases, Brigham and Women s Hospital, 4 Blackfan Circle, HIM 758, Boston, MA 02115, USA
Mol Cell Biol 28:5369-80. 2008....
Median absolute deviation to improve hit selection for genome-scale RNAi screensNamjin Chung
Department of Automated Biotechnology, Merck Research Laboratories, North Wales, PA 19454, USA
J Biomol Screen 13:149-58. 2008....
An efficient and fully automated high-throughput transfection method for genome-scale siRNA screensNamjin Chung
Department of Automated Biotechnology, Merck Research Laboratories, North Wales, PA 19454, USA
J Biomol Screen 13:142-8. 2008..Transfection efficiency, performances of control siRNAs, and other quality metrics were monitored and demonstrated that the new, optimized transfection protocol produced high-quality results throughout the screen...
A microRNA component of the p53 tumour suppressor networkLin He
Watson School of Biological Sciences, Howard Hughes Medical Institute, Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, New York 11724, USA
Nature 447:1130-4. 2007..The p53 network suppresses tumour formation through the coordinated activation of multiple transcriptional targets, and miR-34 may act in concert with other effectors to inhibit inappropriate cell proliferation...
Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studiesRalf Kittler
Max Planck Institute for Molecular Cell Biology and Genetics, Pfotenhauerstrasse 108, D 01307 Dresden, Germany
Nat Methods 4:337-44. 2007..Hence, the presented esiRNA libraries offer an efficient, cost-effective and specific alternative to presently available mammalian RNAi resources...
Gene expression profiling predicts clinical outcome of breast cancerLaura J van 't Veer
Division of Diagnostic Oncology, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands
Nature 415:530-6. 2002..This gene expression profile will outperform all currently used clinical parameters in predicting disease outcome. Our findings provide a strategy to select patients who would benefit from adjuvant therapy...
Designing siRNA that distinguish between genes that differ by a single nucleotideDianne S Schwarz
Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
PLoS Genet 2:e140. 2006..Our data suggest that siRNAs can be designed to discriminate between the wild-type and mutant alleles of many genes that differ by just a single nucleotide...
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptorsJames L Riley
Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104 6160, USA
Proc Natl Acad Sci U S A 99:11790-5. 2002..Cytotoxic T lymphocyte antigen 4 (CTLA-4) engagement selectively blocked augmentation of gene regulations by CD28-mediated costimulation, but did not ablate gene regulation induced by TCR triggering alone...
Synthetic shRNAs as potent RNAi triggersDespina Siolas
Nat Biotechnol 23:227-31. 2005..Maximal inhibition of target genes was achieved at lower concentrations and silencing at 24 h was often greater. These studies provide the basis for an improved approach to triggering experimental silencing via the RNAi pathway...
A large-scale RNAi screen in human cells identifies new components of the p53 pathwayKatrien Berns
Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Nature 428:431-7. 2004..Furthermore, we describe siRNA bar-code screens to rapidly identify individual siRNA vectors associated with a specific phenotype. These new tools will greatly facilitate large-scale loss-of-function genetic screens in mammalian cells...
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanismsRichard V Parry
Abramson Family Cancer Research Institute, 556 BRB II III, 421 Curie Blvd, University of Pennsylvania, Philadelphia, PA 19104, USA
Mol Cell Biol 25:9543-53. 2005..Together, these data suggest that CTLA-4 and PD-1 inhibit T-cell activation through distinct and potentially synergistic mechanisms...
Minimizing the risk of reporting false positives in large-scale RNAi screensChristophe J Echeverri
Cenix BioScience GmbH, Tatzberg 47, Dresden, 10307, Germany
Nat Methods 3:777-9. 2006....
